BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

GlycoVaxyn AG 

Ditch Route 3

Streaks    8952  Switzerland
Phone: 41-44-733-85-85 Fax: 41-44-733-85-74


SEARCH JOBS




Industry
Biotechnology

Segment
Vaccines





 Company News
GlycoVaxyn AG Announces The Initiation Of A Phase I Clinical Trial In Collaboration With Janssen Pharmaceutical Inc. For A Vaccine Against Extra-Intestinal Pathogenic Escherichia Coli Causing Urinary Tract Infection 7/1/2014 9:58:53 AM
GlycoVaxyn AG Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine 7/29/2013 9:17:48 AM
GlycoVaxyn AG Announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors 3/6/2013 6:50:02 AM
GlycoVaxyn AG Signs Exclusive License Agreement and Enters Research and Development Collaboration With Janssen Pharmaceuticals, Inc., to Develop Multi-Valent Bacterial Vaccine 1/4/2013 9:58:53 AM
GlycoVaxyn AG Announces Strategic Collaboration With GlaxoSmithKline (GSK) to Develop New Bacterial Vaccines using GlycoVaxyn's Bio-Conjugation Technology 12/19/2012 9:05:22 AM
GlycoVaxyn AG's Staphylococcus aureus Bioconjugate Vaccine Candidate Protects Mice Against Invasive S. aureus Infection 9/16/2011 10:37:06 AM
GlycoVaxyn AG to Host Second Annual Science Day to Discuss Challenges and Opportunities in Vaccine Development 6/15/2011 7:03:59 AM
GlycoVaxyn AG Phase I Clinical Study Shows Positive Data with Shigella Dysenteriae Vaccine Candidate 10/8/2010 9:39:22 AM
GlycoVaxyn AG and a Harvard University Affiliated Hospital Receive USD 3.4 Million National Institutes of Health (NIH) Grant for Staphylococcus aureus Vaccine Development 5/4/2010 6:59:45 AM
GlycoVaxyn AG's First Clinical Study with Bioconjugate Vaccine Initiated 2/23/2010 9:55:40 AM
12